DE60214127D1 - HYBRIDOMY CELL LINE G250 AND ITS USE FOR THE PRODUCTION OF MONOCLONAL ANTIBODIES - Google Patents

HYBRIDOMY CELL LINE G250 AND ITS USE FOR THE PRODUCTION OF MONOCLONAL ANTIBODIES

Info

Publication number
DE60214127D1
DE60214127D1 DE60214127T DE60214127T DE60214127D1 DE 60214127 D1 DE60214127 D1 DE 60214127D1 DE 60214127 T DE60214127 T DE 60214127T DE 60214127 T DE60214127 T DE 60214127T DE 60214127 D1 DE60214127 D1 DE 60214127D1
Authority
DE
Germany
Prior art keywords
hybridomy
production
cell line
monoclonal antibodies
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60214127T
Other languages
German (de)
Other versions
DE60214127T2 (en
Inventor
Egbert Oosterwijk
Sven Warnaar
Stefan Ullrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heidelberg Pharma AG
Original Assignee
Wilex AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wilex AG filed Critical Wilex AG
Application granted granted Critical
Publication of DE60214127D1 publication Critical patent/DE60214127D1/en
Publication of DE60214127T2 publication Critical patent/DE60214127T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to novel nucleic acid sequences which encode an antibody suitable in the field of tumor diagnostics and therapeutics. Further, a method of producing recombinant antibodies is provided, wherein the novel nucleic acid sequencs are employed.
DE60214127T 2001-02-07 2002-02-07 HYBRIDOMY CELL LINE G250 AND ITS USE FOR THE PRODUCTION OF MONOCLONAL ANTIBODIES Expired - Lifetime DE60214127T2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26685301P 2001-02-07 2001-02-07
US266853P 2001-02-07
US32700801P 2001-10-05 2001-10-05
US327008P 2001-10-05
PCT/EP2002/001282 WO2002062972A2 (en) 2001-02-07 2002-02-07 Hybridoma cell line g250 and its use for producing monoclonal antibodies

Publications (2)

Publication Number Publication Date
DE60214127D1 true DE60214127D1 (en) 2006-10-05
DE60214127T2 DE60214127T2 (en) 2007-01-11

Family

ID=26952068

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60214127T Expired - Lifetime DE60214127T2 (en) 2001-02-07 2002-02-07 HYBRIDOMY CELL LINE G250 AND ITS USE FOR THE PRODUCTION OF MONOCLONAL ANTIBODIES

Country Status (13)

Country Link
US (1) US20040219633A1 (en)
EP (2) EP1358318B8 (en)
JP (1) JP4263485B2 (en)
AT (1) ATE337395T1 (en)
AU (2) AU2002238537B8 (en)
CA (1) CA2435683C (en)
DE (1) DE60214127T2 (en)
DK (2) DK1733736T3 (en)
ES (2) ES2266448T3 (en)
HK (1) HK1094876A1 (en)
MX (1) MXPA03006992A (en)
PT (2) PT1733736E (en)
WO (2) WO2002063010A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077081A1 (en) 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
AU2003280442B2 (en) 2002-07-01 2009-02-05 Wilex Ag Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas
JP2008505143A (en) * 2004-07-02 2008-02-21 ヴィレックス アクチェンゲゼルシャフト Improved adjuvant therapy for G250 expressing tumors
US8466263B2 (en) 2005-12-02 2013-06-18 Dana-Farber Cancer Institute, Inc. Carbonic anhydrase IX (G250) anitbodies
DOP2006000277A (en) * 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp ANTI MN ANTIBODIES AND METHODS FOR USE
WO2008091798A2 (en) * 2007-01-22 2008-07-31 Xencor, Inc. Optimized ca9 antibodies and methods of using the same
GB0911569D0 (en) * 2009-07-03 2009-08-12 Ulive Entpr Ltd Method for the detection of organ or tissue injury
RU2536290C2 (en) * 2009-09-15 2014-12-20 Вилекс Аг Selective detection of bone metastases in clear cell renal cell adenocarcinoma
AU2014220705C1 (en) * 2013-02-22 2018-10-18 Wilex Ag CAIX stratification based cancer treatment
BR112021026651A2 (en) * 2019-07-02 2022-03-03 Telix Int Pty Ltd Antibodies against coffin with reduced affinity for the neonatal fc receptor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU6032786A (en) * 1985-07-25 1987-01-29 University Of Minnesota Detection, imaging and therapy of renal cell carcinoma with monoclonal antibodies in vivo
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
WO1988008854A1 (en) * 1987-05-06 1988-11-17 Egbert Oosterwijk Monoclonal antibodies to renal cell carcinoma
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69616651D1 (en) * 1995-05-26 2001-12-13 Merck Patent Gmbh Antiidiotypic antibodies that induce an immune response against the receptor for epidermal growth factor
US6057098A (en) * 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
DK2180007T4 (en) * 1998-04-20 2017-11-27 Roche Glycart Ag Glycosylation technique for antibodies to enhance antibody-dependent cell cytotoxicity
FR2793497B1 (en) * 1999-05-10 2003-04-18 Centre Nat Rech Scient MONOCLONAL ANTIBODIES DIRECTED AGAINST HUMAN RENAL CARCINOMA CELLS
KR20020092886A (en) * 1999-07-06 2002-12-12 고트-아-겐 에이비 Recombinant adenovirus
GB0017720D0 (en) * 2000-07-19 2000-09-06 Got A Gene Ab Modified virus
WO2003016909A1 (en) * 2001-08-16 2003-02-27 Ludwig Institute For Cancer Research Method for determining protein component in a biological sample

Also Published As

Publication number Publication date
AU2002252999A1 (en) 2002-08-19
WO2002063010A2 (en) 2002-08-15
WO2002062972A2 (en) 2002-08-15
HK1094876A1 (en) 2007-04-13
WO2002062972A3 (en) 2002-12-12
US20040219633A1 (en) 2004-11-04
ATE337395T1 (en) 2006-09-15
MXPA03006992A (en) 2003-11-18
AU2002238537B2 (en) 2006-07-20
EP1358318A2 (en) 2003-11-05
CA2435683A1 (en) 2002-08-15
DE60214127T2 (en) 2007-01-11
WO2002063010A9 (en) 2002-09-12
ES2531909T3 (en) 2015-03-20
AU2002238537B8 (en) 2006-08-24
JP2004522447A (en) 2004-07-29
DK1733736T3 (en) 2015-06-01
JP4263485B2 (en) 2009-05-13
EP1358318B8 (en) 2006-11-15
EP1358318B1 (en) 2006-08-23
WO2002063010A3 (en) 2003-11-27
PT1358318E (en) 2007-01-31
DK1358318T3 (en) 2007-01-02
ES2266448T3 (en) 2007-03-01
PT1733736E (en) 2015-06-11
CA2435683C (en) 2012-03-20
EP1385959A2 (en) 2004-02-04

Similar Documents

Publication Publication Date Title
HK1094876A1 (en) Method of producing recombinant antibodies against tumours
EA200700249A1 (en) RECOMBINANT POLYCLLONAL ANTIBODY AGAINST THE CENTRAL FACTOR D AND METHODS FOR ITS OBTAINING
DE602008002593D1 (en) METHOD FOR PRODUCING A RECOMBINANT POLYCLONAL PROTEIN
ATE501170T1 (en) METHOD FOR PRODUCING HUMANIZED ANTIBODIES BY RANDOMIZED MUtagenesis
ATE469917T2 (en) METHOD FOR OBTAINING ANTIBODIES
NZ600584A (en) Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
DK1414858T3 (en) Camelide single-chain VHH antibodies, method for their preparation in a mammal, and uses thereof
ATE444308T1 (en) FUSION PROTEINS OF HUMANIZED G250 SPECIFIC ANTIBODIES AND USES THEREOF
ATE405644T1 (en) METHOD FOR PRODUCING AND PURIFYING ERYTHROPOIETIN
ATE439380T1 (en) METHODS FOR PRODUCING HUMAN MONOCLONAL ANTIBODIES
ATE448246T1 (en) SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS FOR THE ENCODING THEM
ATE418609T1 (en) METHOD FOR THE CONTINUOUS TARGETED EVOLUTION OF PROTEINS IN VITRO
ATE500331T1 (en) METHOD FOR THE SIMULTANEOUS PRODUCTION OF MULTIPLE PROTEINS; VECTORS AND CELLS USED FOR THIS
DE60137847D1 (en) EG-VEGF NUCLEIC ACIDS AND POLYPEPTIDES AND METHOD FOR THE USE THEREOF
ATE407987T1 (en) NEW MESOGENS, METHOD FOR THEIR PRODUCTION AND USE
DE60310562D1 (en) METHOD FOR REINFORCING AN IMMUNE RESPONSE OF NUCLEIC ACID VACCINATION
DE60335195D1 (en) MUTANT E. COLI-APPA-PHYTASEENZYME AND NATURAL VARIANTS THEREOF, SUCH NUCLEIC ACIDS CODING PHYTASEASE SYMBOLS, VECTORS AND HOST CELLS CONTAINING THEREOF, AND METHOD FOR THE PREPARATION AND USE THEREOF
MXPA03010523A (en) Antibodies specific for cd44v6.
ATE360065T1 (en) METHOD FOR PRODUCING TEMPLATES DNA AND METHOD FOR PROTEIN PRODUCTION IN A CELL-FREE PROTEIN SYNTHESIS SYSTEM USING SAME
DE60314132D1 (en) METHOD FOR THE PRODUCTION OF MONOCLONAL ANTIBODIES
DE60026733D1 (en) HISTONE DEACETYLASE-8 PROTEINS, NUCLEIC ACIDS AND METHODS OF USE
DE502004007067D1 (en) PROCESS FOR PRODUCING CYCLIC MOLECULES
ATE408029T1 (en) METHOD FOR PRODUCING AND IDENTIFYING SOLUBLE PROTEIN DOMAIN
ATE423467T1 (en) METHOD FOR PRODUCING GENETICALLY MODIFIED ANTIBODY PRODUCING CELL LINES WITH IMPROVED ANTIBODY PROPERTIES
DE60329594D1 (en) Method for producing a polypeptide, an RNA or another compound in tumor tissue

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: OOSTERWIJK, EGBERT, NL-6641 BEUNINGEN, NL

Inventor name: WARNAAR, SVEN, NL-2334 LEIDEN, NL

Inventor name: ULLRICH, STEFAN, DR., 82319 STARNBERG, DE

8364 No opposition during term of opposition